Zuellig Pharma Strengthens Healthcare Access in Thailand
Zuellig Pharma's purpose is clear: to make healthcare more accessible. From digital innovations and cold chain logistics to local partnerships with institutions such as Thammasat University Hospital, the company is working to bridge the healthcare access gap, particularly in areas such as weight-related conditions and chronic disease management. These efforts are central to its wider mission in the region.
Investing in Innovation for a Healthier Thailand
Thailand is moving quickly to approve innovative treatments and therapies, creating a fertile ground for strategic alliances. Zuellig Pharma has responded by forging partnerships with global biopharmaceutical companies to bring cutting-edge treatments to Thai patients faster. These include solutions supporting chronic disease management and advanced treatments for complex conditions.
Through its commercial and distribution services, Zuellig Pharma plays a key role in connecting life-changing therapies with local healthcare providers, accelerating patient access and supporting healthcare professionals with essential tools and knowledge.
Building Infrastructure to Reach the Hardest-to-Reach
The expanded Samut Prakan distribution centre now boasts a storage capacity of 1,800 pallets, a dedicated ultra-low temperature freezer room (-20°C to -30°C) for specialty medicines, and advanced temperature control systems. This upgrade reflects Zuellig Pharma's readiness to support a new generation of temperature-sensitive, high-value medicines and vaccines.
Sustainability and safety are also at the heart of the investment. Fire protection systems, sustainable packaging such as the proprietary eZCooler, and automated defrost systems contribute to efficient, secure, and environmentally conscious operations—ensuring safe last-mile deliveries to even the most remote communities.
Supporting Thai People through Public–Private Partnerships
Central to Zuellig Pharma's approach is collaboration. The company has formed long-term partnerships with Thai universities and healthcare institutions to promote innovation and workforce development. A standout example is its alliance with Action4Diabetes (A4D), a non-profit working across seven Southeast Asian countries, including Thailand, to close care gaps for children with Type 1 diabetes.
Since 2017, Zuellig Pharma has supported A4D with logistics, supply chain expertise, and regional distribution capabilities—most recently delivering life-saving care packs to families affected by the March 2025 Myanmar earthquake, in collaboration with local charity City Love & Hope Foundation.
During the COVID-19 pandemic, Zuellig Pharma provided essential logistics services by helping to distribute millions of vaccine doses nationwide. This reflects its agility and deep-rooted commitment to supporting Thailand in times of need.
Thailand's Role in Zuellig Pharma's ASEAN Growth Strategy
With its dynamic healthcare system, forward-looking regulations, and strategic location, Thailand plays a vital role in Zuellig Pharma's regional vision.
'Thailand has always been a cornerstone of Zuellig Pharma's presence in Asia,' said John Graham, Group CEO of Zuellig Pharma. 'With its dynamic healthcare landscape, progressive regulatory environment, and deep talent pool, the country plays a pivotal role in shaping our regional growth strategy. Our continued investment here reflects not only our confidence in Thailand's long-term potential, but also our commitment to ensuring that innovative, life-changing medicines are accessible to every community — no matter how remote.'
A Long-Term Vision for Healthcare Access
Zuellig Pharma's presence in Thailand is more than a business strategy—it's a commitment to sustainable healthcare progress. From pioneering supply chain innovation to supporting local healthcare partners, the company remains a trusted ally in the country's journey toward health equity.
As the region prepares for a future shaped by ageing populations and increasing demand for complex therapies, Zuellig Pharma stands ready to meet the challenge—ensuring that no patient is left behind.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bangkok Post
a day ago
- Bangkok Post
Beauty clinics harness tech for new surgeries
Beauty clinics in Thailand are differentiating themselves by incorporating the latest technology to meet client needs, according to a dermatologist. Competition in the Thai beauty industry is expected to continue growing this year, with a projected market value of 76.5 billion baht, representing 2.8% year-on-year growth, driven by a greater number of clients and rising treatment costs, said Dr Nicha Kaewprasom, a board-certified dermatologist at Eleven i Clinic. She said several beauty clinics are looking for ways to differentiate themselves in this highly competitive market. Among these clinics, EndoliftX technology has become a revolutionary laser treatment for lifting and tightening skin, as well as reducing fat, she said. This non-surgical, non-anaesthesia, and scarless procedure utilises a micro-optical fibre to deliver laser energy into the skin, she added. Dr Nicha noted that this technology offers a remarkable alternative for facelifts and options for body contouring. As one of the first medical teams in Thailand to try EndoliftX technology, she said she had found this to be a revolutionary and highly effective method in treating skin laxity and fat melting, especially in some specific areas where traditional methods are not addressed. Dr Nicha has played a role in developing protocols and treatment procedures designed to suit the skin structure of Asians, which differs from that of Westerners in terms of the condition and its responsiveness to laser energy. She said Thailand is currently the leader in EndoliftX technology in Asia because it is the first country to have seriously implemented it and achieved effective results for many patients.
Bangkok Post
6 days ago
- Bangkok Post
Thailand cracks down on ‘zombie pods' drug
Thai authorities are tightening restrictions on the drug etomidate to curb its use in potentially deadly vape products known as 'zombie pods'. Currently, the anaesthetic etomidate is regulated as a specially controlled substance, and can be used only by doctors in medical centres for specific procedures or operations. In several recent cases, however, the anaesthetic has been found mixed with liquid for e-cigarettes, according to the Food and Drug Administration (FDA). The use of 'zombie pods' that can lead to addiction among vape users is prevalent in China, Hong Kong and Taiwan, and is rising in Thailand, the FDA said on Thursday. To prevent more dangerous cases, etomidate will be listed as a Psychotropic Substance Category 2, effective from July 27. Illegal possession carries penalties of up to seven years in prison and/or up to 700,000 baht in fines. Sellers can face up to 15 years in prison and/or up to 1.5 million baht in fines.
Bangkok Post
6 days ago
- Bangkok Post
Zuellig Pharma Strengthens Healthcare Access in Thailand
As Thailand navigates a shifting healthcare landscape marked by ageing populations and rising rates of chronic illnesses, Zuellig Pharma—a leading healthcare solutions provider in Asia—is doubling down on its commitment to the Kingdom. With over 75 years of local presence and more than a century of experience across Asia, the company's recent THB 130 million investment in expanding its distribution centre in Samut Prakan is more than an infrastructure upgrade—it's a bold signal of long-term partnership with Thailand's health system. Zuellig Pharma's purpose is clear: to make healthcare more accessible. From digital innovations and cold chain logistics to local partnerships with institutions such as Thammasat University Hospital, the company is working to bridge the healthcare access gap, particularly in areas such as weight-related conditions and chronic disease management. These efforts are central to its wider mission in the region. Investing in Innovation for a Healthier Thailand Thailand is moving quickly to approve innovative treatments and therapies, creating a fertile ground for strategic alliances. Zuellig Pharma has responded by forging partnerships with global biopharmaceutical companies to bring cutting-edge treatments to Thai patients faster. These include solutions supporting chronic disease management and advanced treatments for complex conditions. Through its commercial and distribution services, Zuellig Pharma plays a key role in connecting life-changing therapies with local healthcare providers, accelerating patient access and supporting healthcare professionals with essential tools and knowledge. Building Infrastructure to Reach the Hardest-to-Reach The expanded Samut Prakan distribution centre now boasts a storage capacity of 1,800 pallets, a dedicated ultra-low temperature freezer room (-20°C to -30°C) for specialty medicines, and advanced temperature control systems. This upgrade reflects Zuellig Pharma's readiness to support a new generation of temperature-sensitive, high-value medicines and vaccines. Sustainability and safety are also at the heart of the investment. Fire protection systems, sustainable packaging such as the proprietary eZCooler, and automated defrost systems contribute to efficient, secure, and environmentally conscious operations—ensuring safe last-mile deliveries to even the most remote communities. Supporting Thai People through Public–Private Partnerships Central to Zuellig Pharma's approach is collaboration. The company has formed long-term partnerships with Thai universities and healthcare institutions to promote innovation and workforce development. A standout example is its alliance with Action4Diabetes (A4D), a non-profit working across seven Southeast Asian countries, including Thailand, to close care gaps for children with Type 1 diabetes. Since 2017, Zuellig Pharma has supported A4D with logistics, supply chain expertise, and regional distribution capabilities—most recently delivering life-saving care packs to families affected by the March 2025 Myanmar earthquake, in collaboration with local charity City Love & Hope Foundation. During the COVID-19 pandemic, Zuellig Pharma provided essential logistics services by helping to distribute millions of vaccine doses nationwide. This reflects its agility and deep-rooted commitment to supporting Thailand in times of need. Thailand's Role in Zuellig Pharma's ASEAN Growth Strategy With its dynamic healthcare system, forward-looking regulations, and strategic location, Thailand plays a vital role in Zuellig Pharma's regional vision. 'Thailand has always been a cornerstone of Zuellig Pharma's presence in Asia,' said John Graham, Group CEO of Zuellig Pharma. 'With its dynamic healthcare landscape, progressive regulatory environment, and deep talent pool, the country plays a pivotal role in shaping our regional growth strategy. Our continued investment here reflects not only our confidence in Thailand's long-term potential, but also our commitment to ensuring that innovative, life-changing medicines are accessible to every community — no matter how remote.' A Long-Term Vision for Healthcare Access Zuellig Pharma's presence in Thailand is more than a business strategy—it's a commitment to sustainable healthcare progress. From pioneering supply chain innovation to supporting local healthcare partners, the company remains a trusted ally in the country's journey toward health equity. As the region prepares for a future shaped by ageing populations and increasing demand for complex therapies, Zuellig Pharma stands ready to meet the challenge—ensuring that no patient is left behind.
